Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system
“Compensation for Blindness with the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy (IRIS 2)”
Pixium Vision (Paris:PIX) (FR0011950641 – PIX), a company developing innovative bionic vision systems that aim to allow patients who have lost their sight to lead more independent lives, today announced that it has been awarded CE mark for its IRIS®II bionic vision system. This 150-electrode epi-retinal implant features a design intended to be explantable and upgradeable. The IRIS®II system is now CE mark approved for people with vision loss from outer retinal degeneration.
Christina Fasser, President of Retina International, an umbrella association of 33 national societies, said: “The progress in research with vision restoration of some visual perception is a reality, particularly with retinal prostheses. This research is addressing the growing patients’ expectations and their hope to regain some sight. On behalf of our member organisations, we are delighted to welcome the new bionic vision system IRIS®II that may offer people suffering from retinitis pigmentosa a new treatment option with a design that is intended to be explantable and upgradeable.”
IRIS®II incorporates innovative and distinctive features:
- A bio-inspired camera intended to mimic the functioning of the human eye by continuously capturing the changes in a visual scene with its time independent pixels, and unlike an imaging sensor that takes a sequence of video frames with largely redundant information;
- An epi-retinal implant with 150 electrodes – almost three times the number of electrodes than previous version;
- An explantable design: the electrode array is secured on the retinal surface by a patented support system that is intended to allow for explantation or future replacements or upgrades…..
- Read more: http://www.businesswire.com/news/home/20160724005058/en/Pixium-Vision%C2%A0announces-CE-market-approval-IRIS%C2%AEII-bionic Source: Business Wire